Information  X 
Enter a valid email address

Company Name matching 'Galapagos NV'

Date
Time Source
Company
Announcement
08 Aug 2022 9:01 pm GNW   Galapagos NV Galapagos receives transparency notification from FMR LLC
04 Aug 2022 9:01 pm GNW   Galapagos NV First key steps in pipeline rebuild and strong commercial progress in H1 2022
21 Jun 2022 9:03 pm GNW   Galapagos NV Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
20 Jun 2022 9:01 pm GNW   Galapagos NV Galapagos increases share capital through subscription right exercises
01 Jun 2022 9:01 pm GNW   Galapagos NV Galapagos receives transparency notification from FMR LLC
25 May 2022 9:01 pm GNW   Galapagos NV Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress
06 May 2022 9:01 pm GNW   Galapagos NV Galapagos creates new subscription right plans
05 May 2022 9:01 pm GNW   Galapagos NV Galapagos demonstrates regulatory and commercial progress in Q1 2022
26 Apr 2022 9:01 pm GNW   Galapagos NV Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
28 Mar 2022 7:01 am GNW   Galapagos NV Jyseleca® approved in Japan for ulcerative colitis
24 Mar 2022 8:17 pm GNW   Galapagos NV Correction: Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings
18 Mar 2022 9:01 pm GNW   Galapagos NV Galapagos increases share capital through subscription right exercises
24 Feb 2022 9:01 pm GNW   Galapagos NV Galapagos 2021 results set stage for future growth
03 Feb 2022 9:01 pm GNW   Galapagos NV Galapagos receives transparency notification from EcoR1 Capital
02 Feb 2022 9:01 pm GNW   Galapagos NV Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress
26 Jan 2022 9:40 pm GNW   Galapagos NV Galapagos creates new subscription right plan
  9:01 pm GNW   Galapagos NV Galapagos appoints Paul Stoffels as Chief Executive Officer
18 Jan 2022 9:01 pm GNW   Galapagos NV JYSELECA® (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN    
13 Jan 2022 9:01 pm GNW   Galapagos NV Galapagos creates new subscription right plan
06 Jan 2022 2:30 pm GNW   Galapagos NV Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
03 Dec 2021 9:01 pm GNW   Galapagos NV Galapagos increases share capital through subscription right exercises
22 Nov 2021 9:01 pm GNW   Galapagos NV Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
15 Nov 2021 3:45 pm GNW   Galapagos NV Jyseleca®(filgotinib) approved in the European Union for the treatment of ulcerative colitis
04 Nov 2021 9:01 pm GNW   Galapagos NV Galapagos reports commercial and operational progress at Q3 financial results
04 Oct 2021 9:01 pm GNW   Galapagos NV Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
  6:01 am GNW   Galapagos NV Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
20 Sep 2021 9:01 pm GNW   Galapagos NV Galapagos increases share capital through subscription right exercises
17 Sep 2021 12:15 pm GNW   Galapagos NV GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
30 Aug 2021 9:01 pm GNW   Galapagos NV Galapagos announces planned retirement of CEO
05 Aug 2021 9:01 pm GNW   Galapagos NV Galapagos reports H1 financial results with refocused pipeline and operational progress
14 Jul 2021 9:01 pm GNW   Galapagos NV Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
  9:01 pm GNW   Galapagos NV Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
10 Jul 2021 10:10 am GNW   Galapagos NV Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis
22 Jun 2021 9:01 pm GNW   Galapagos NV Galapagos announces departure of CSO Piet Wigerinck later this year
07 Jun 2021 9:01 pm GNW   Galapagos NV Galapagos increases share capital through subscription right exercises
04 Jun 2021 6:01 am GNW   Galapagos NV SELECTION study on filgotinib in ulcerative colitis published in The Lancet
27 May 2021 9:01 pm GNW   Galapagos NV Galapagos to present data on rheumatoid arthritis at the upcoming European League Against Rheumatism (EULAR) congress
18 May 2021 9:01 pm GNW   Galapagos NV Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting
06 May 2021 9:01 pm GNW   Galapagos NV Galapagos refocuses pipeline and rightsizes operations  
04 May 2021 9:01 pm GNW   Galapagos NV Transparency notification received from The Capital Group
30 Apr 2021 9:01 pm GNW   Galapagos NV Galapagos creates new subscription right plans
23 Apr 2021 5:01 am GNW   Galapagos NV Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies
08 Apr 2021 9:01 pm GNW   Galapagos NV Extension of lock-up period in Gilead-Galapagos collaboration agreement
25 Mar 2021 8:01 pm GNW   Galapagos NV Publication of the annual report and invitation to the ordinary shareholders’ meeting
24 Mar 2021 8:01 pm GNW   Galapagos NV Galapagos appoints Bart Filius as President and Chief Operating Officer
19 Mar 2021 9:01 pm GNW   Galapagos NV Galapagos increases share capital through subscription right exercises
04 Mar 2021 6:49 am GNW Factsheet Galapagos NV (GLPG) GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING FILGOTINIB MANTA AND MANTA-RAy SAFETY STUDIES
03 Mar 2021 9:15 pm GNW Factsheet Galapagos NV (GLPG) Transparency notification received from The Capital Group
18 Feb 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) Pipeline and capital for growth
10 Feb 2021 2:00 pm GNW Factsheet Galapagos NV (GLPG) Galapagos and Gilead discontinue ISABELA Phase 3 trials in IPF
09 Feb 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) The Capital Group holds 10.03% of Galapagos shares
21 Jan 2021 7:08 am GNW Factsheet Galapagos NV (GLPG) NICE recommends Jyseleca® ▼(filgotinib) on NHS in landmark decision for rheumatoid arthritis
11 Jan 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) Gilead holds 25.54% of Galapagos shares
06 Jan 2021 2:30 pm GNW Factsheet Galapagos NV (GLPG) Galapagos to present at 39th Annual J.P. Morgan Healthcare Conference
04 Jan 2021 9:01 pm GNW Factsheet Galapagos NV (GLPG) Selvita completes acquisition of Fidelta from Galapagos
23 Dec 2020 5:00 pm GNW Factsheet Galapagos NV (GLPG) Galapagos’ CEO makes donation of €10 million in the form of personal shares to African Parks
15 Dec 2020 9:15 pm GNW Factsheet Galapagos NV (GLPG) Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  Jyseleca® (filgotinib)  
04 Dec 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos increases share capital through subscription right exercises
01 Dec 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos announces first dosing in MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
30 Nov 2020 9:01 pm GNW Factsheet Galapagos NV (GLPG) Galapagos reports positive topline results with GLPG1205 in IPF patients in PINTA Proof-of-Concept trial 


Company Announcements Archive »


a d v e r t i s e m e n t